efinopegdutide vs survodutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

MASH / NASH

Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline

efinopegdutide

Developed by Merck & Co.

Phase 2 in MASH / NASHpeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

survodutide

Developed by Boehringer Ingelheim under a licence from Zealand Pharma

Phase 3 in MASH / NASHpeptide
Reliable signal

NCT06309992 · Phase 3 · completed

This phase 3 trial randomly assigned 216 adults with obesity and at-risk MASLD (2:1) to weekly survodutide 6.0 mg or placebo, with double-blind treatment for 48 weeks. The first co-primary endpoint was a reduction of at least 30% in liver fat on MRI: 84.2% of survodutide patients reached it against 24.3% on placebo (P<0.0001). The second co-primary endpoint was body weight change: -12.2% against -1.0% (P<0.0001). Both co-primary endpoints were met, so the result is met. The figures come from the peer-reviewed Nature Medicine paper.

Next expected readout: April 2029 · NCT07850063 (registry estimate)

Reported efficacy

Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%] (at baseline, at week 48); Relative change (%) in body weight [kg] from baseline to Week 48 (at baseline, at week 48): Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met. (met)

Result source: NCT06309992

Results for MASH / NASH

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointefinopegdutidesurvodutide
MASH resolution without fibrosis worsening—Not reported—Not posted · NCT06309992
Fibrosis stage, change—Not reported—Not posted · NCT06309992
Liver fat (MRI-PDFF), change—Not reported-13.0% vs -1.9%−11.1 vs placebo6.0 mg · wk 48 · n 51NCT04771273
11 other results
  • -12.5% vs -1.6% 6.0 mg · wk 48 · n 58 · Phase 2 · secondary NCT04771273
  • -64.3% vs -7.3% 6.0 mg · wk 48 · n 51 · Phase 2 · secondary NCT04771273
  • -62.0% vs -5.7% 6.0 mg · wk 48 · n 58 · Phase 2 · secondary NCT04771273
  • -12.8% vs -1.9% 4.8 mg · wk 48 · n 60 · Phase 2 · secondary NCT04771273
  • -12.4% vs -1.6% 4.8 mg · wk 48 · n 64 · Phase 2 · secondary NCT04771273
  • -62.8% vs -7.3% 4.8 mg · wk 48 · n 60 · Phase 2 · secondary NCT04771273
  • -60.8% vs -5.7% 4.8 mg · wk 48 · n 64 · Phase 2 · secondary NCT04771273
  • -10.5% vs -1.9% 2.4 mg · wk 48 · n 68 · Phase 2 · secondary NCT04771273
  • -10.7% vs -1.6% 2.4 mg · wk 48 · n 61 · Phase 2 · secondary NCT04771273
  • -50.9% vs -7.3% 2.4 mg · wk 48 · n 68 · Phase 2 · secondary NCT04771273
  • -52.2% vs -5.7% 2.4 mg · wk 48 · n 61 · Phase 2 · secondary NCT04771273
ALT, change—Not reported—Not posted · NCT06309992

MASH resolution without fibrosis worsening

efinopegdutide
—Not reported
survodutide
—Not posted · NCT06309992

Fibrosis stage, change

efinopegdutide
—Not reported
survodutide
—Not posted · NCT06309992

Liver fat (MRI-PDFF), change

efinopegdutide
—Not reported
survodutide
-13.0% vs -1.9%−11.1 vs placebo6.0 mg · wk 48 · n 51NCT04771273
11 other results
  • -12.5% vs -1.6% 6.0 mg · wk 48 · n 58 · Phase 2 · secondary NCT04771273
  • -64.3% vs -7.3% 6.0 mg · wk 48 · n 51 · Phase 2 · secondary NCT04771273
  • -62.0% vs -5.7% 6.0 mg · wk 48 · n 58 · Phase 2 · secondary NCT04771273
  • -12.8% vs -1.9% 4.8 mg · wk 48 · n 60 · Phase 2 · secondary NCT04771273
  • -12.4% vs -1.6% 4.8 mg · wk 48 · n 64 · Phase 2 · secondary NCT04771273
  • -62.8% vs -7.3% 4.8 mg · wk 48 · n 60 · Phase 2 · secondary NCT04771273
  • -60.8% vs -5.7% 4.8 mg · wk 48 · n 64 · Phase 2 · secondary NCT04771273
  • -10.5% vs -1.9% 2.4 mg · wk 48 · n 68 · Phase 2 · secondary NCT04771273
  • -10.7% vs -1.6% 2.4 mg · wk 48 · n 61 · Phase 2 · secondary NCT04771273
  • -50.9% vs -7.3% 2.4 mg · wk 48 · n 68 · Phase 2 · secondary NCT04771273
  • -52.2% vs -5.7% 2.4 mg · wk 48 · n 61 · Phase 2 · secondary NCT04771273

ALT, change

efinopegdutide
—Not reported
survodutide
—Not posted · NCT06309992
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

efinopegdutide: no structured comparison results are available for MASH / NASH.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. efinopegdutide: 0 of 4 rows · survodutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsurvodutide
Dropout rate
—6.0 mga
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
24%6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
13.7%4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
15.1%2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—6.0 mga
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
16%6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
12.3%4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
11%2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
Serious AEs
9.6%6.0 mga
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
—6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
10.1%4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
5.4%2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
6.0 mga
nausea 63.5% (placebo 27.8%)
diarrhoea 55.8% (placebo 25.3%)
constipation 28.8% (placebo 17.7%)
NCT04771273 · Phase 2 · registry result, not featured evidence
show 2 more results
4.8 mg
nausea 66.7% (placebo 27.8%)
diarrhoea 53.6% (placebo 25.3%)
vomiting 47.8% (placebo 7.6%)
NCT04771273 · Phase 2 · registry result, not featured evidence
2.4 mg
nausea 64.5% (placebo 27.8%)
diarrhoea 40.9% (placebo 25.3%)
vomiting 40.9% (placebo 7.6%)
NCT04771273 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

survodutide

Histologic Improvement 55.8% (n=52) vs 15.2% (n=79) placebo @ 48wk6.0 mg
responder rate · % of participants
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
43.2% (n=74) vs 13.5% (n=74) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
63.8% (n=69) vs 15.2% (n=79) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
62.5% (n=72) vs 13.5% (n=74) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
38.7% (n=93) vs 15.2% (n=79) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
46.6% (n=73) vs 13.5% (n=74) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
MRI-PDFF ≥30% 76.9% (n=52) vs 16.5% (n=79) placebo @ 48wk6.0 mg
responder rate · % of participants
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
56.8% (n=74) vs 13.5% (n=74) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
66.7% (n=69) vs 16.5% (n=79) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
66.7% (n=72) vs 13.5% (n=74) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
50.5% (n=93) vs 16.5% (n=79) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
63% (n=73) vs 13.5% (n=74) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
Liver Fat -12.96% (n=51) vs -1.89% (n=73) placebo @ 48wk6.0 mg
absolute change · percentage points
NCT04771273 · Phase 2 · registry result, not featured evidence
show 11 more results
-12.48% (n=58) vs -1.61% (n=69) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-64.3% (n=51) vs -7.28% (n=73) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-61.97% (n=58) vs -5.71% (n=69) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-12.8% (n=60) vs -1.89% (n=73) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-12.4% (n=64) vs -1.61% (n=69) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-62.79% (n=60) vs -7.28% (n=73) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-60.82% (n=64) vs -5.71% (n=69) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-10.48% (n=68) vs -1.89% (n=73) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-10.73% (n=61) vs -1.61% (n=69) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-50.92% (n=68) vs -7.28% (n=73) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-52.2% (n=61) vs -5.71% (n=69) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
Fibrosis Improvement 1-Stage Without NASH Worsening 44.2% (n=52) vs 21.5% (n=79) placebo @ 48wk6.0 mg
responder rate · % of participants
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
33.8% (n=74) vs 21.6% (n=74) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
34.8% (n=69) vs 21.5% (n=79) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
36.1% (n=72) vs 21.6% (n=74) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
30.1% (n=93) vs 21.5% (n=79) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
34.2% (n=73) vs 21.6% (n=74) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
NAS -3.3 vs -0.4 placebo score @ 48wk6.0 mg
absolute change · score
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
-3.3 vs -0.2 placebo score @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-3.2 vs -0.4 placebo score @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-3.2 vs -0.2 placebo score @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-2.8 vs -0.4 placebo score @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-2.8 vs -0.2 placebo score @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efinopegdutide's landscape · survodutide's landscape